A six-year study in a real-world population reveals an increased incidence of dyslipidemia during COVID-19, 2024, Trimarco et al.

Discussion in 'Long Covid research' started by SNT Gatchaman, Nov 4, 2024.

  1. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    5,923
    Location:
    Aotearoa New Zealand
    A six-year study in a real-world population reveals an increased incidence of dyslipidemia during COVID-19
    Valentina Trimarco; Raffaele Izzo; Stanislovas S. Jankauskas; Mario Fordellone; Giuseppe Signoriello; Maria Virginia Manzi; Maria Lembo; Paola Gallo; Giovanni Esposito; Roberto Piccinocchi; Francesco Rozza; Carmine Morisco; Pasquale Mone; Gaetano Piccinocchi; Fahimeh Varzideh; Bruno Trimarco; Gaetano Santulli

    BACKGROUND
    Recent studies conducted in individuals who survived COVID-19 suggest that SARS-CoV-2 infection is associated with an increased risk of dyslipidemia. However, it remains unclear whether this augmented risk is confirmed in the general population and how this phenomenon is affecting the overall burden of cardiometabolic diseases.

    METHODS
    To address these aspects, we conducted a 6-year longitudinal study to examine the broader effects of COVID-19 on dyslipidemia incidence in a real-world population (228,266 individuals) residing in Naples in southern Italy. The pre–COVID-19 and COVID-19 groups were balanced for demographic and clinical factors using propensity score matching.

    RESULTS
    Our analysis spans a period of 3 years during the COVID-19 pandemic (2020–2022), comparing dyslipidemia incidence with pre-pandemic data (2017–2019), with a follow-up of at least 1,095 days corresponding to 21,349,215 personyears. During the COVID-19 period, we detected an increased risk of developing any dyslipidemia when compared with the pre–COVID-19 triennium (OR = 1.29; 95% CI, 1.19–1.39). Importantly, these estimates were adjusted for comorbidities by a multivariate analysis.

    CONCLUSIONS
    Taken together, our data reveal a notable rise in dyslipidemia incidence during the COVID-19 pandemic, suggesting the utility of establishing specialized clinical monitoring protocols for patients who survive COVID-19 to mitigate the risk of developing dyslipidemia.

    Link | PDF (The Journal of Clinical Investigation) [Open Access]
     
  2. Sly Saint

    Sly Saint Senior Member (Voting Rights)

    Messages:
    9,998
    Location:
    UK
    I can't see mention of liver problems behind devpt of dyslipidemia; also dysbiosis of gut microbiome can also impact.
     
    alktipping, Peter Trewhitt and Amw66 like this.

Share This Page